Apex Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Apex Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$30.9M	Buy	1,867,677 +156,588	+9%	+$2.74M	0.68%	61
2015 Q4	$37.1M	Buy	1,711,089 +13,548	+0.8%	+$264K	0.83%	49
2015 Q3	$33.6M	Buy	1,697,541 +673,072	+66%	+$21.3M	0.76%	60
2015 Q2	$35.6M	Buy	1,024,469 +634,811	+163%	+$19.4M	0.76%	58
2015 Q1	$10.1M	Buy	+389,658	New	+$7.14M	0.24%	90

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Apex Capital Management's HZNP Position: Q1 2016 in Review

Apex Capital Management increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 9.2% in Q1 2016, buying an estimated $2.74M and bringing the position to 1,867,677 shares worth $30.9M. The position accounts for 0.68% of the portfolio, ranked #61.

Apex Capital Management first reported a position in HZNP in Q1 2015 and has held it in 5 quarters since. The position peaked at $37.1M in Q4 2015. 196 funds tracked by Wall St. Rank hold HZNP as of Q1 2016.

Apex Capital Management held 1,867,677 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $30.9M as of Q1 2016.
Apex Capital Management bought 156,588 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2016, an estimated $2.74M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.68% of Apex Capital Management's portfolio in Q1 2016, its #61 holding.
Apex Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and has held it in 5 quarters since.
Apex Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $37.1M in Q4 2015.
196 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.